Straits Times Index
3,287.29 -5.40 (-0.16%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,202.37 +439.34 (+2.47%) FTSE 100
8,150.19 +28.95 (+0.36%) Bitcoin USD
57,627.88 -1.07 (-0.00%) CMC Crypto 200
1,264.15 -6.60 (-0.52%)
Swedish Orphan Biovitrum AB (B6E.HA)
| Previous close | 23.98 |
| Open | 23.90 |
| Bid | 24.06 x N/A |
| Ask | 24.28 x N/A |
| Day's range | 23.90 - 23.90 |
| 52-week range | 16.32 - 25.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
PR NewswireSobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
PR NewswireNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
